Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | PLAU | P00749 | 4/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29600590 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A2SLC6A4PLAUALPL | |
| SCHEMBL18883017 | 0.91 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4PLAUALPL | |
| SCHEMBL7815690 | 0.89 | PLAU (0.71) | SLC6A3SLC6A2SLC6A4PLAUALPL | |
| SCHEMBL15009048 | 0.84 | RARB (0.55) | PLAUCYP11B1CYP11B2CYP19A1KDM4E | |
| SCHEMBL14743822 | 0.81 | PLAU (0.63) | PLAUCYP11B1CYP11B2CYP19A1SIRT2 | |
| SCHEMBL1003761 | 0.80 | KDM4E (0.62) | SLC6A3SLC6A2SLC6A4PLAUCYP11B1 | |
| SCHEMBL13900228 | 0.80 | CYP11B1 (0.69) | SLC6A3SLC6A2SLC6A4PLAUCYP11B1 | |
| SCHEMBL7823750 | 0.80 | TSHR (0.63) | KDM4EALDH1A1TSHR | |
| SCHEMBL2355805 | 0.80 | PLAU (0.56) | SLC6A3SLC6A2SLC6A4PLAUALPL | |
| SCHEMBL269272 | 0.80 | PLAU (0.52) | PLAUCYP11B1CYP11B2CYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | WU YONG-QIAN (US) | 2004-08-12 | — | — | US | disclosed |
| US-6656971-B2 | Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions | GUILFORD PHARMACEUTICALS INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1360173-A2 | TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE | GUILFORD PHARMACEUTICALS INC. (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002059080-A2 | TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE | GUILFORD PHARMACEUTICALS INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157919-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | SLC6A3 4401/4885SLC6A2 4305/4885SLC6A4 3983/4885 |
| US-20020165275-A1 | Trisubstituted carbocyclic cyclophilin binding compounds and their use | FKBP2, PPIG, FKBP8 | SLC6A3 4401/4885SLC6A2 4305/4885SLC6A4 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.